MARKET

BLI

BLI

Berkeley Lights, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

81.28
+4.01
+5.19%
After Hours: 81.28 0 0.00% 16:00 12/04 EST
OPEN
77.58
PREV CLOSE
77.27
HIGH
82.16
LOW
77.44
VOLUME
210.52K
TURNOVER
--
52 WEEK HIGH
98.93
52 WEEK LOW
50.26
MARKET CAP
4.95B
P/E (TTM)
-233.0275
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Is Berkeley Lights (BLI) a Smart Long-term Buy?
Insider Monkey · 1d ago
Medigus, Aptevo Therapeutics leads healthcare gainers; MeiraGTx Holdings, Kintara Therapeutics among major losers
Gainers: Medigus (MDGS) +30%, Aptevo Therapeutics (APVO) +29%, Corcept Therapeutics (CORT) +23%, Opiant Pharmaceuticals (OPNT) +15%, Aquestive Therapeutics (AQST) +11%.Losers: MeiraGTx Holdings (MGTX) -11%, Kintara Therapeutics (KTRA) -10%, Berkeley Lights (BLI) -10%, Kazia Therapeutics (KZIA) -8%, Immutep (IMMP) -7%.
Seekingalpha · 11/19 16:00
Berkeley Lights Announces Pricing of 3M Share Public Offering by Selling Stockholders @$86/Share
Berkeley Lights, Inc. (NASDAQ: BLI) announced the pricing of its previously announced public offering of 3,000,000 shares of common stock to be sold by certain selling stockholders of Berkeley Lights at a public offering price of $86.00 per share.
Benzinga · 11/19 10:55
Berkeley Lights prices secondary offering at $86
Digital Cell Biology company, Berkeley Lights (BLI) has priced its public offering of 3M common shares to be sold by certain selling stockholders at $86.00/share.Underwriters' over-allotment is an additional 450K
Seekingalpha · 11/19 04:50
Berkeley Lights Announces Launch of Public Offering by Selling Stockholders
EMERYVILLE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc., a leader in Digital Cell Biology, today announced the launch of a public offering of 3,000,000 shares of common stock to be sold by certain selling stockholders of Berkeley Lights. In addition, the selling stockholders are expected to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock. The selling stockholders will receive all of the net proceeds from the offering. Berkeley Lights will not receive any proceeds from the offering. J.P. Morgan, Morgan Stanley and Cowen are acting as lead book-running managers for the offering.A registration statement relating to the shares being sold in this offering by the selling stockholders has been filed with the Securities and Exchange Commission but has not yet become effective. The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone: +1 (866) 803-9204, or by emailing prospectus-eq_fi@jpmchase.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; and Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: +1 (833) 297-2926, or by emailing PostSaleManualRequests@broadridge.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.About Berkeley LightsBerkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.Berkeley Lights’ Beacon and Lightning systems and Culture Station instrument are For Research Use Only. Not for use in diagnostic procedures.Forward-Looking StatementsTo the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding completion, timing and size of the proposed public offering that involve risks and uncertainties, including, without limitation, risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering. Such forward-looking statements involve substantial risks and uncertainties that relate to future events and the actual results could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the business of the Company in general, see the preliminary prospectus for this offering included as part of the Registration Statement on Form S-1 related to the proposed offering filed with the SEC, and its future periodic reports to be filed with the SEC.Press Contactberkeleylights@bulleitgroup.comInvestor Contactir@berkeleylights.com
GlobeNewswire · 11/16 21:21
Morgan Stanley Maintains Equal-Weight on Berkeley Lights, Raises Price Target to $80
Morgan Stanley maintains Berkeley Lights (NASDAQ:BLI) with a Equal-Weight and raises the price target from $65 to $80.
Benzinga · 11/16 13:08
Berkeley Lights EPS beats by $0.03, beats on revenue
Berkeley Lights (BLI): Q3 GAAP EPS of -$0.16 beats by $0.03.Revenue of $18.21M (+16.2% Y/Y) beats by $2.96M.Press Release
Seekingalpha · 11/12 21:31
Berkeley Lights Q3 EPS $(0.16) Beats $(0.20) Estimate, Sales $18.20M Beat $15.29M Estimate
Berkeley Lights (NASDAQ:BLI) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. The company reported quarterly sales of $18.20 million which beat the
Benzinga · 11/12 21:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLI. Analyze the recent business situations of Berkeley Lights, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLI stock price target is 92.33 with a high estimate of 100.00 and a low estimate of 80.00.
EPS
Institutional Holdings
Institutions: 74
Institutional Holdings: 17.35M
% Owned: 28.47%
Shares Outstanding: 60.94M
TypeInstitutionsShares
Increased
0
0
New
74
17.35M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.48%
Healthcare Equipment & Supplies
+1.33%
Key Executives
Chief Executive Officer/Director
Eric Hobbs
Co-Founder/Independent Director
Igor Khandros
Chief Financial Officer/Primary Contact
Shaun Holt
Senior Vice President/Chief Accounting Officer
Matthew Rosinack
Chief Technology Officer
Keith Breinlinger
General Counsel
Stuart Merkadeau
Other
Kevin Chapman
Director
Sarah Boyce
Director
Michael Marks
Director
Elizabeth Nelson
Director
James Rothman
Independent Director
Gregory Lucier
Independent Director
Michael Moritz
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BLI
Berkeley Lights, Inc. is a Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The Company has developed the Berkeley Lights Platform to provide the advanced environment for rapid functional characterization of single cells at scale. The Berkeley Lights Platform consists of advanced automated systems that analyze live cells using consumables and application and workflow software to deliver robust single cell data. Its platform characterizes the performance of cells relevant to the desired cell-based product early in the process and then connects this phenotypic data to the genetic code for each cell. The Berkeley Lights Platform is a fully integrated, end-to-end solution, comprised of consumables, including its OptoSelect chips and reagent kits, advanced automation systems and advanced application and workflow software.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Berkeley Lights Inc stock information, including NASDAQ:BLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLI stock methods without spending real money on the virtual paper trading platform.